SCHEMBL19355183

SCHEMBL19355183

CCOC(=O)NCC(O)CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 4/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 1/20 0.39
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
KDM4E B2RXH2 1/20 0.36
DUSP3 P51452 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 1/20 0.36
GLA P06280 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17790872 0.85 ACHE (0.44) LMNAKDM4EDUSP3SMN1; SMN2NPC1
SCHEMBL9682338 0.82 ACHE (0.51) KMT2AMEN1LMNAALDH1A1KDM4E
SCHEMBL9117583 0.81 GAA (0.46) GAAKMT2AMEN1LMNAALDH1A1
SCHEMBL7108962 0.81 EPHX1 (0.38) KMT2AMEN1LMNAALDH1A1MAPT
SCHEMBL7108959 0.81 EPHX1 (0.38) KMT2AMEN1LMNAALDH1A1MAPT
SCHEMBL3171650 0.81 ACHE (0.41) KMT2AGLAACHE
SCHEMBL3171657 0.81 ACHE (0.41) KMT2AGLAACHE
SCHEMBL19355186 0.81 SMN1; SMN2 (0.46) KMT2AMEN1LMNAALDH1A1HSD17B10
SCHEMBL18904583 0.80 ACHE (0.47) LMNASMN1; SMN2TSHRNPC1RAB9A
SCHEMBL17791086 0.80 LMNA (0.34) LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258741-A1 FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY CATABASIS PHARMACEUTICALS, INC. (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258741-A1 FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY NDUFAB1, ATG7, HADHA GAA 481/4885KMT2A 1811/4885MEN1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.